Monte Rosa Therapeutic (GLUE) Wells Fargo 21st Annual Healthcare Conference summary

Strategic focus and platform overview

• Focused on targeted protein degradation, specifically molecular glue degraders, with three clinical assets and more expected in the next 12 months.

• Platform leverages AI and internal data to design selective degraders, supporting a robust and expanding pipeline.

• Main therapeutic areas are autoimmune disease, immunology and inflammation, and oncology.

Lead program MRT-8102 and NEK7 targeting

• MRT-8102 targets NEK7, a scaffolding protein in the NLRP3 inflammasome, aiming to prevent inflammasome assembly and sterile inflammation.

• Lead indication is ASCVD, supported by strong preclinical, genetic, and clinical evidence linking NLRP3 to cardiovascular disease.

• GFORCE-1 phase I trial includes multi-dose, eight-week safety observation, measuring biomarkers like DAMPs, calprotectin, and CRP.

• Safety profile expected to be favorable compared to downstream targets like IL-6, as NEK7 inhibition preserves broader immune function.

Indication selection and development path

• Indications chosen based on RNA-Seq data showing pathway upregulation; ASCVD, gout, and hidradenitis suppurativa (HS) prioritized.

• Gout program focuses on reducing flare recurrence post-acute treatment, aiming for rapid proof of concept.

• HS trial design is being finalized, with initiation planned after other indications.